Single-agent liposomal all-trans retinoic acid can cure some patients with untreated acute promyelocytic leukemia: An update of The University of Texas M. D. Anderson Cancer Center Series

Leukemia and Lymphoma

Volumn 47, Issue 6, 2006, Pages 1062-1068

  Tsimberidou, Apostolia Maria ^a   Tirado Gomez, Maribel ^a   Andreeff, Michael ^a   O'Brien, Susan ^a   Kantarjian, Hagop ^a   Keating, Michael ^a   Lopez Berestein, Gabriel ^a   Estey, Elihu ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

All trans retinoic acid; APL; Liposomal; Molecular remission; White blood cell count

Indexed keywords

CORTICOSTEROID; IDARUBICIN; LIPOSOME; MERCAPTOPURINE; METHOTREXATE; PREDNISONE; RETINOIC ACID; RETINOIC ACID RECEPTOR ALPHA; VINCRISTINE;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGE; AGED; ARTHRALGIA; ARTICLE; CANCER CENTER; CANCER CHEMOTHERAPY; CANCER REGRESSION; CANCER RELAPSE; CANCER SURVIVAL; CARDIOTOXICITY; CLINICAL ARTICLE; CLINICAL OBSERVATION; CONTROLLED STUDY; DRUG DOSE REGIMEN; DRUG FORMULATION; DRUG RESPONSE; HEADACHE; HUMAN; HUMAN CELL; INFECTIOUS PNEUMONIA; LEUKOCYTE COUNT; MONOTHERAPY; MUCOSA INFLAMMATION; MULTIVARIATE ANALYSIS; MYCOSIS; MYELODYSPLASTIC SYNDROME; NAUSEA AND VOMITING; PNEUMONIA; POLYMERASE CHAIN REACTION; PREDICTION; PRIORITY JOURNAL; PROMYELOCYTIC LEUKEMIA; PROPORTIONAL HAZARDS MODEL; RISK ASSESSMENT; SENSITIVITY ANALYSIS; SEPSIS; SURVIVAL RATE; SURVIVAL TIME; UNITED STATES; UNIVERSITY HOSPITAL;

ADULT; AGED; ANTIBIOTICS, ANTINEOPLASTIC; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; IDARUBICIN; LEUKEMIA, PROMYELOCYTIC, ACUTE; LIPOSOMES; MALE; MIDDLE AGED; RECEPTORS, RETINOIC ACID; REMISSION INDUCTION; TEXAS; TRETINOIN;

EID: 33746320763     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.1080/10428190500463932     Document Type: Article

References (36)

1. Gilliland, D and Jordan, C and Felix, C. (2004) The molecular basis of leukemia Hematology (Am Soc Hematol Educ Program), pp. 80-97.
2. Huang, M and Ye, Y and Chen, S and Chai, J and Lu, J and Zhoa, L and et al. (1988) Use of all-trans retinoic acid in the treatment of acute promyelocytic leukemia Blood, 72, pp. 567-572.
3. Wang, Z and Sun, G and Lu, J and Gu, L and Huang, M and Chen, S. (1990) Treatment of acute promyelocytic leukemia with all-trans retinoic acid in China Nouvelle Revue Francaise d Hematologie, 32, pp. 34-36.
4. Estey, E and Thall, P and Pierce, S and Kantarjian, H and Keating, M. (1997) Treatment of newly diagnosed acute promyelocytic leukemia without cytarabine J Clin Oncol, 15, pp. 483-490.
5. Tallman, M and Nabhan, C and Feusner, J and Rowe, J. (2002) Acute promyelocytic leukemia: Evolving therapeutic strategies Blood, 99, pp. 759-767.
6. Zompi, S and Legrand, O and Bouscary, D and Blanc, C and Picard, F and Casadevall, N and et al. (2000) Therapy-related acute myeloid leukaemia after successful therapy for acute promyelocytic leukaemia with t (15;17): A report of two cases and a review of the literature Br J Haematol, 110, pp. 610-613.
7. Au, W and Lam, C and Ma, E and Man, C and Wan, T and Kwong, Y. (2001) Therapy-related myelodysplastic syndrome after eradication of acute promyelocytic leukemia: Cytogenetic and molecular features Hum Pathol, 32, pp. 126-129.
8. Latagliata, R and Petti, M and Fenu, S and Mancini, M and Spiriti, M and Breccia, M and et al. (2002) Therapy-related myelodysplastic syndrome-acute myelogenous leukemia in patients treated for acute promyelocytic leukemia: An emerging problem Blood, 99, pp. 822-824.
9. Ozpolat, B and Lopez-Berestein, G and Adamson, P and Fu, C and Williams, A. (2003) Pharmacokinetics of intravenously administered liposomal all-trans-retinoic acid and orally administered ATRA in healthy volunteers J Pharm Pharm Sci, 6, pp. 292-301.
10. Estey, E and Giles, F and Kantarjian, H and O'Brien, S and Cortes, J and Freireich, E and et al. (1999) Molecular remissions induced by liposomal-encapsulated all-trans retinoic acid in newly diagnosed acute promyelocytic leukemia Blood, 94, pp. 2230-2235.
11. Estey, E and Koller, C and Tsimberidou, A and O'Brien, S and Beran, M and Cortes, J and et al. (2005) Potential curability of newly diagnosed acute promyelocytic leukemia without use of chemotherapy: The example of liposomal all-trans retinoic acid Blood, 105, pp. 1366-1367.
12. Thall, P and Estey, E.(2001) Graphical methods for evaluating covariate effects in the Cox model. In Handbook of Statistics in Clinical Oncology. (pp. 411-432). New York: Marcel Dekker.
13. Tallman, M and Andersen, J and Schiffer, C and Appelbaum, F and Feusner, J and Ogden, A and et al. (2000) Clinical description of 44 patients with acute promyelocytic leukemia who developed the retinoic acid syndrome Blood, 95, pp. 90-95.
14. Fenaux, P and Chastang, C and Chevret, S and Sanz, M and Dombret, H and Archimbaud, E and et al. (1999) A randomized comparison of all transretinoic acid (ATRA) followed by chemotherapy and ATRA plus chemotherapy and the role of maintenance therapy in newly diagnosed acute promyelocytic leukemia. The European APL Group Blood, 94, pp. 1192 - 1200.
15. Fenaux, P and Chevret, S and Guerci, A and Fegueux, N and Dombret, H and Thomas, X and et al. (2000) Long-term follow-up confirms the benefit of all-trans retinoic acid in acute promyelocytic leukemia. European APL group Leukemia, 14, pp. 1371-1377.
16. Tallman, M and Andersen, J and Schiffer, C and Appelbaum, F and Feusner, J and Woods, W and et al. (2002) All-trans retinoic acid in acute promyelocytic leukemia: Long-term outcome and prognostic factor analysis from the North American Intergroup protocol Blood, 100, pp. 4298-4302.
17. Tallman, M and Andersen, J and Schiffer, C and Appelbaum, F and Feusner, J and Ogden, A and et al. (1997) All-trans-retinoic acid in acute promyelocytic leukemia N Engl J Med, 337, pp. 1021-1028.
18. Sanz, M and Martin, G and Rayon, C and Esteve, J and Gonzalez, M and Diaz-Mediavilla, J and (1999) A modified AIDA protocol with anthracycline-based consolidation results in high antileukemic efficacy and reduced toxicity in newly diagnosed PML/RARalpha-positive acute promyelocytic leukemia. PETHEMA group Blood, 94, pp. 3015 - 3021.
19. Dombret, H and Fenaux, P and Soignet, S and Tallman, M. (2002) Established practice in the treatment of patients with acute promyleocytic leukemia and the introduction of arsenic trioxide as a novel therapy Semin Hematol, 39, pp. 8-13.
20. Sanz, M and Martin, G and Gonzalez, M and Leon, A and Rayon, C and Rivas, C and (2004) Risk-adapted treatment of acute promyelocytic leukemia with all-trans-retinoic acid and anthracycline monochemotherapy: A multicenter study by the PETHEMA group Blood, 103, pp. 1237-1243.
21. Tallmann, M. (2004) Curative therapeutic approaches to APL Ann Hematol, 83(Suppl 1), pp. S81-S82.
22. Shen, Z and Chen, G and Ni, J and Li, X and Xiong, S and Qiu, Q and (1997) Use of arsenic trioxide in the treatment of acute promyelocytic leukemia: Clinical efficacy and pharmacokinetics in relapsed patients Blood, 89, pp. 3354-3360.
23. Niu C and Yan, H and Yu, T and Sun, H and Liu, J and Li, X and et al. (1999) Studies on treatment of acute promyelocytic leukemia with arsenic trioxide: Remission induction, follow-up, and molecular monitoring in 11 newly diagnosed and 47 relapsed acute promyelocytic leukemia patients Blood, 94, pp. 3315-3324.
24. Soignet, S and Maslak, P and Wang, Z and Jhanwar, S and Calleja, E and Dardashti, L and et al. (1998) Complete remission after treatment of acute promyelocytic leukemia with arsenic trioxide N Engl J Med, 339, pp. 1341-1348.
25. Soignet, S and Frankel, S and Douer, D and Tallman, M and Kantarjian, H and Calleja, E and (2001) United States multicenter study of arsenic trioxide in relapsed acute promyelocytic leukemia J Clin Oncol, 19, pp. 3852-3860.
26. Ohnishi, K and Yoshida, H and Shigeno, K and Nakamura, S and Fujisawa, S and Naito, K and et al. (2002) Arsenic trioxide therapy for relapsed or refractory Japanese patients with acute promyelocytic leukemia: Need for careful electrocardiogram monitoring Leukemia, 16, pp. 617-622.
27. Lazo, G and Kantarjian, H and Estey, E and Thomas, D and O'Brien, S and Cortes, J. (2003) Use of arsenic trioxide (As2O3) in the treatment of patients with acute promyelocytic leukemia: The MD. Anderson experience Cancer, 97, pp. 2218-2224.
28. Petti, M and Pinazzi, M and Diverio, D and Romano, A and Petrucci, M and De Santis, S and et al. (2001) Prolonged molecular remission in advanced acute promyelocytic leukaemia after treatment with gemtuzumab ozogamicin Br J Haematol, 115, pp. 63-65.
29. Estey, E and Giles, F and Beran, M and O'Brien, S and Pierce, S and Faderl, S and et al. (2002) Experience with gemtuzumab ozogamycin and all-trans retinoic acid in untreated acute promyelocytic leukemia Blood, 99, pp. 4222-4224.
30. Lo Coco, F and Cimino, G and Breccia, M and Noguera, N and Diverio, D and Finolezzi, E and et al. (2004) Gemtuzumab ozogamicin (Mylotarg) as a single agent for molecularly relapsed acute promyelocytic leukemia Blood, 104, pp. 1995-1999.
31. Douer, D and Hu, W and Giralt, S and Lill, M and DiPersio, J. (2003) Arsenic trioxide therapy for acute promyelocytic leukemia in the setting of hematopoietic stem cell transplantation Oncologist, 8, pp. 132-140.
32. de Botton, S and Fawaz, A and Chevret, S and Dombret, H and Thomas, X and Sanz, M and et al. (2005) Autologous and allogeneic stem-cell transplantation as salvage treatment of acute promyelocytic leukemia initially treated with all-trans-retinoic acid: A retrospective analysis of the European acute promyelocytic leukemia group J Clin Oncol, 23, pp. 120-126.
33. Lo-Coco, F and Romano, A and Mengarelli, A and Diverio, D and Iori, A and Moleti, M and (2003) Allogeneic stem cell transplantation for advanced acute promyelocytic leukemia: Results in patients treated in second molecular remission or with molecularly persistent disease Leukemia, 17, pp. 1930-1933.
34. Thomas, X and Dombret, H and Cordonnier, C and Pigneux, A and Gardin, C and Guerci, A and (2000) Treatment of relapsing acute promyelocytic leukemia by all-trans retinoic acid therapy followed by timed sequential chemotherapy and stem cell transplantation. APL Study Group. Acute promyelocytic leukemia Leukemia, 14, pp. 1006-1013.
35. Shen, Z and Shi, Z and Fang, J and Gu, B and Li, J and Zhu, Y and et al. (2004) All-trans retinoic acid/As2O3 combination yields a high quality remission and survival in newly diagnosed acute promyelocytic leukemia Proc Natl Acad Sci USA, 101, pp. 5328-5335.
36. Fenaux, P and Castaigne, S and Chomienne, C and Dombret, H and Degos, L. (1992) All trans retinoic acid treatment for patients with acute promyelocytic leukemia Leukemia, 6(Suppl 1), pp. 64-66.